Use for deferiprone

Abstract

A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat induced cardiac disease normally associated with iron overload.

1 . (canceled)  
   
   
       2 . (canceled)  
   
   
       3 . (canceled)  
   
   
       4 . (canceled)  
   
   
       5 . (canceled)  
   
   
       6 . (canceled)  
   
   
       7 . (canceled)  
   
   
       8 . A pharmaceutical composition comprising an effective therapeutic amount of deferiprone or a physiologically acceptable salt thereof for the prevention of heart disease in transfusion dependent patients experiencing iron overload and sufficient to treat iron induced cardiac disease normally associated with iron overload.  
   
   
       9 . A pharmaceutical composition comprising an effective therapeutic amount of deferiprone or a physiologically acceptable salt thereof for the stabilization of heart disease in transfusion dependent patients experiencing iron overload and sufficient to treat iron induced cardiac disease normally associated with iron overload.  
   
   
       10 . A pharmaceutical composition comprising an effective therapeutic amount of deferiprone or a physiologically acceptable salt thereof for the reduction of heart disease in transfusion dependent patients experiencing iron overload and sufficient to treat iron induced cardiac disease normally associated with iron overload.  
   
   
       11 . (canceled)  
   
   
       12 . (canceled)  
   
   
       13 . (canceled)  
   
   
       14 . (canceled)  
   
   
       15 . (canceled)  
   
   
       16 . (canceled)  
   
   
       17 . (canceled)  
   
   
       18 . A pharmaceutical composition comprising a therapeutically effective amount of deferiprone or physiologically acceptable salt thereof for the prevention, treatment, or reversal of heart disease in transfusion dependent patients experiencing an iron overload condition of the heart and to preferentially reduce the iron stores in the heart in comparison to the iron stores in other organs/tissue in the body.  
   
   
       19 . (canceled)  
   
   
       20 . (canceled)  
   
   
       21 . (canceled)  
   
   
       22 . (canceled)  
   
   
       23 . (canceled)  
   
   
       24 . (canceled)  
   
   
       25 . (canceled)  
   
   
       26 . (canceled)  
   
   
       27 . (canceled)  
   
   
       28 . (canceled)  
   
   
       29 . (canceled)  
   
   
       30 . (canceled)  
   
   
       31 . (canceled)  
   
   
       32 . (canceled)  
   
   
       33 . (canceled)  
   
   
       34 . (canceled)  
   
   
       35 . (canceled)  
   
   
       36 . (canceled)  
   
   
       37 . (canceled)  
   
   
       38 . (canceled)  
   
   
       39 . (canceled)  
   
   
       40 . (canceled)  
   
   
       41 . (canceled)  
   
   
       42 . (canceled)  
   
   
       43 . (canceled)  
   
   
       44 . (canceled)  
   
   
       45 . (canceled)  
   
   
       46 . (canceled)  
   
   
       47 . (canceled)  
   
   
       48 . (canceled)  
   
   
       49 . (canceled)  
   
   
       50 . (canceled)  
   
   
       51 . (canceled)  
   
   
       52 . (canceled)  
   
   
       53 . (canceled)  
   
   
       54 . The pharmaceutical composition of claims  8 ,  9 ,  10  and  18  further comprising an oral dosage form of deferiprone or a physiologically acceptable salt thereof with other excipients.  
   
   
       55 . The pharmaceutical composition of claims  8 ,  9 ,  10  and  18  further comprising daily administration of an amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of up to 150 mg/kg of body weight.  
   
   
       56 . The pharmaceutical composition of claims  8 ,  9 ,  10  and  18  further comprising administration of a daily dosage amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of up to 125 mg/kg of body weight.  
   
   
       57 . The pharmaceutical composition of claims  8 ,  9 ,  10  and  18  further comprising administration of a daily dosage amount of deferiprone or a physiologically acceptable salt thereof substantially in the range of 25 mg/kg to 75 mg/kg of body weight.  
   
   
       58 . The pharmaceutical composition of claims  8 ,  9 ,  10  and  18  is administered in a manner selected from the group of intravenously, transdermally, rectally, orally, bucally, or aurally.  
   
   
       59 . The pharmaceutical composition of  claim 58  wherein deferiprone is administered orally.  
   
   
       60 . The pharmaceutical composition of claims  8 ,  9 ,  10  and  18  wherein the composition is in a sustained release formulation.  
   
   
       61 . The pharmaceutical composition of claims  8 ,  9 ,  10  and  18  wherein deferiprone has a cardio preferred/selective function when compared to desferrioxamine or other alternative chelating agents utilized in patients suffering iron overload.  
   
   
       62 . The pharmaceutical composition of claims  8 ,  9 ,  10  and  18  wherein desferrioxamine is administered in addition to deferiprone.